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Foreword | 5
Cancer is the second most common cause of death in the EU and breast cancer, 
in particular, is the most common cancer among females in the European Union.
The European Commission Initiative on Breast Cancer is the tangible demon-
stration of what Europe can achieve working in synergy with Member States, the 
scientific community, civil society and patient organisations.
The European Commission Initiative on Breast Cancer today boasts the most 
inclusive expert groups within the EU, and they have been given the mandate to 
develop and deliver guidelines and a quality assurance scheme on breast cancer 
screening, diagnosis and care.
Under the European Commission’s Joint Research Centre coordination, the 
group of experts dedicated to the development of European Guidelines for Breast 
Cancer Screening and Diagnosis are now publishing the first four European Breast 
Guidelines’ recommendations. This publication will ensure that any organisation, 
programme or authority in the Member States, as well as every European citizen, 
can gain access to the recommended standards and procedures, with the view of 
reaching our shared European objective of promoting health and preventing hu-
man illness and diseases.
The recommendations and information about their development will be easy 
to access online through a user-friendly interface, and easily understandable by 
everyone thanks to a clear and comprehensible wording.
It is my hope that these recommendations will improve and strengthen breast 
cancer care and will help save countless lives in the future.
John F. Ryan
Director
European Commission, DG Health and Food Safety, Directorate C–Public Health
Foreword
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The authors would like to acknowledge the valuable work of the Guidelines Devel-
opment Group (GDG1) and the CCIb (Iberoamerican Cochrane Centre2) team 
for the development of European Breast Guidelines recommendations.
1. http://ecibc.jrc.ec.europa.eu/guidelines-team.
2. http://es.cochrane.org/home.
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Policy context
The Written Declaration of the European Parliament on the fight against breast 
cancer in the European Union (0017-2015) states that in order to reduce the breast 
cancer mortality rate, it is important to implement nationwide mammography 
screening programmes and provide comprehensive breast cancer care, as called 
for in the European Parliament resolutions of 2003 and 2006 and foreseen to be 
facilitated by the development of the European guidelines for breast cancer 
screening and diagnosis (European Breast Guidelines) and the European quality 
assurance scheme for breast cancer services (European QA Scheme).
This report intends to inform stakeholders, policy makers in particular, about the 
methods used and outcomes delivered in the European Breast Guidelines within 
the European Commission Initiative on Breast Cancer (ECIBC). As a result of a 
complex process, involving a wide range of experts and patients, evidence-based 
recommendations on screening and diagnosis are being formulated to support the 
countries in defining relevant policies and strategies.
Key conclusions
The major impact of the European Breast Guidelines on EU policy is foreseen in the 
screening area, possible leading to updating needs for the Council Recommenda-
tions of 2003 on cancer screening. Screening is a population based intervention 
and, for instance, screening recommendations concerning the different age-ranges 
of women to be invited/covered by screening and/or the different techniques to 
be used may have a great impact on health policies across the EU, and beyond.
The recommendations related to diagnosis, where costly investments may or may 
not be required will be of interest to policy makers, as well. In addition, the devel-
opment of European Breast Guidelines will also contribute to several EU initiatives, 
summarised in the following figure.
Executive summary
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Fig. 1. Contribution of the European Breast Guidelines to EU initiatives.
Main findings
The European Breast Guidelines will contain six chapters: Screening, Diagnosis, 
Communication, Training, Interventions to reduce inequalities, Monitoring and 
evaluation of screening and diagnosis.
These chapters have been defined by the ‘Guidelines Development Group’ (GDG), 
created in July 2015 following a call for expression of interest organised by DG 
SANTE. Each chapter will include specific recommendations, based on the ques-
tions, relevant to the target audience, that are prioritised by the GDG. The whole 
work of the dedicated subgroups is coordinated by the JRC. The workflow for pro-
duction of the evidence-based recommendations, applying the GRADE (Grading 
of Recommendations Assessment, Development and Evaluation) system, is pre-
sented in Fig. 2. Other related activities and processes complementing the work-
flow include calls for feedback (on the scope of the European Breast Guidelines, on 
the final recommendations), management of conflict of interests, organisation of 
meetings and on-line voting, collaboration with other ongoing projects.
Inequalities in health Making national  
statistics as reliable  
and comparable  
as possible
Supporting  
public-awareness  
raising campaigns
Complementing  
EU-level  
cooperation
• A dedicated chapter  
of the European Breast 
Guidelines will include 
evidence-based recom-
mendations to reduce  
inequalities in screening 
and diagnosis.
• The experts, contribut-
ing to Monitoring and 
evaluation chapter of 
the European Breast 
Guidelines will define 
process and outcome 
indicators, which 
will be comparable 
between countries 
and will be poten-
tially monitored at 
population level in 
order to measure the 
effectiveness of the 
relevant interventions 
regarding screening 
and diagnosis.
• The Communication  
chapter of the 
European Breast 
Guidelines will include 
evidence-based 
recommendations 
about the appropriate 
approach for informing 
the society, individuals 
and high-risk groups 
about benefits and 
harms of screening.
• CANCON–European 
Guide on Quality  
Improvement in 
Comprehensive Cancer 
Control.
• EPAAC–European 
Partnership for Action 
Against Cancer.
• Commission Expert 
Group on Cancer Control.
• European Code Against 
Cancer.
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Fig. 2. The workflow for production of evidence-based recommendations, included in the European 
Breast Guidelines.
Related and future JRC work
The JRC will define a methodology to assess the need and periodicity for updating 
the European Breast Guidelines. The lifecycle of this process will include identifi-
cation of research gaps and search for the best available evidence, which might 
contribute to the revision of recommendations. Moreover, the process of devel-
opment of the recommendations can be used as an example for an appropriate 
approach to be applied also for other types of cancers or other diseases.
 
Quick guide
In order to reduce the breast cancer mortality rate, it is important for European 
countries to implement nationwide mammography screening and provide com-
prehensive breast cancer care. To facilitate these activities, the European Breast 
Guidelines are under development, which will include evidence-based recommen-
dations, formulated as a result of a complex process, involving a wide range of 
experts and patients, applying the GRADE (Grading of Recommendations Assess-
ment, Development and Evaluation) system. The recommendations will support 
relevant EU and country-specific policy decisions and strategies.
Prioritisation  
of the European 
Breast Guidelines 
questions
Actors: GDG, JRC
Framing  
the questions
P - Population
I - Intervention
C - Comparator
O - Outcomes
Actors: GDG, JRC
Search  
for evidence 
related t0 each 
question and 
rating the quality 
of evidence
Actors: CCIb, 
GDG, JRC
Going from the 
evidence to the 
recommendation– 
Evidence-to- 
decision 
frameworks
Actors: GDG, 
CCIb, JRC
Recommendations
Actors: GDG, JRC
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The European Commission Directorate-General Health and Food Safety (DG 
SANTE) has the policy leadership on the EU health-related policies. Cancer con-
trol activities are prioritised within these policies, among other reasons, due to 
the impact on population health and the inequalities in quality of care across 
Members States.
On the one hand, Europe carries a significant load of the global cancer burden, 
while on the other hand there are evidence-based strategies proven to be success-
ful to reduce this burden, such as prevention and early-detection programmes, 
including screening. The implementation of these programmes is not uniform 
across Europe and depends very much on the policies in place in the different 
countries and the organisation of healthcare and available resources, among other 
reasons. As a result, outcomes for people with cancer vary and this inequality has 
to be addressed in a proper way. Therefore, in order to support national policies 
on cancer control, DG SANTE has taken forward several initiatives on cancer–the 
European Commission Initiative on Breast Cancer (ECIBC) being one of them.
The ECIBC started in December 2012 and is coordinated by the Commission’s 
Joint Research Centre (JRC).
1. Introduction
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2.1. Breast cancer incidence, mortality and survival
An estimated 464000 women were diagnosed with breast cancer in Europe in 
2012. Breast cancer (BC) was the leading cancer site among women in all European 
countries, accounting for 29% of all new female cases that year. In the same year, 
131000 women were estimated to die from BC, accounting for 17% of all female 
cancer deaths in Europe and making it the most common cause of female cancer 
death [1]. The incidence of BC has continued to increase in almost all European 
countries in recent decades, while mortality rates have fallen in many countries 
since the mid-1990s, but not in all European regions [2]. Five-year survival of 
women with BC is 82% with variations from 74% in Eastern Europe to 85% in 
Northern Europe [3], indicating possible inequalities in BC care for European 
women.
2.2. Legal framework
While it is up to national governments to organise healthcare and ensure that it is 
provided, the European Commission (EC) supports national policies coordinat-
ing development of guidelines and recommendations. Thus, following the Council 
Recommendation on cancer screening 3 from December 2003, the 4th edition of the Euro­
pean Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis 4 was 
produced, including best practices defined by consensus of experts. Moreover, the 
Consolidated Treaty of the EU 5 (2007), the European Parliament Resolution 6 (2008) the 
Council Conclusions on reducing the burden of cancer 7 (2008) and several other official 
documents [4] [5] [6] [7] also contributed to emphasise the strong determination 
3. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:327:0034:0038:EN:PDF.
4. http://bookshop.europa.eu/en/european-guidelines-for-quality-assurance-in-breast-cancer-screening-and-diagnosis-pb 
ND7306954/.
5. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:2016:202:TOC.
6. http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+TA+P6-TA-2008-0121+0+DOC+XML+V0/ 
/EN.
7. http://www.eu2008.si/en/News_and_Documents/Council_Conclusions/June/0609_EPSCO-cancer.pdf.
2. Background
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to tackle these issues at European level–recognising breast cancer screening as an 
effective strategy for reducing cancer risk and mortality, and underlying the need 
for comprehensive strategies for breast cancer control.
3. Methods | 13
The main objectives of the ECIBC project are two: 1) to propose evidence-based 
recommendations on screening and care for breast cancer services in Europe and 
2) to develop a voluntary European quality assurance (QA) scheme for Breast 
Cancer Services. In order to achieve these objectives, two working groups, the 
‘Guidelines Development Group’ (GDG) and the ‘Quality Assurance Scheme 
Development Group’ (QASDG), were created in July 2015 following a call for 
expression of interest organised by DG SANTE. The selection process was accord-
ing to the rules for establishing scientific and consultative groups in the European 
Union. The GDG and QASDG contribute to the development of the European 
Guidelines for Breast Cancer Screening and Diagnosis (European Breast Guidelines) 
and the European QA scheme, respectively.
For both groups a transparent policy for management of potential Conflict of 
Interests 8 was put in place and is applied to minimise the risk that voting/deci-
sions would be biased. A more detailed overview on how independence is granted 
within ECIBC is given in chapter 4.1 below.
The European Breast Guidelines are developed applying GRADE 9 (Grading of 
Recommenda tions Assessment, Development and Evaluation). Increasingly be-
ing adopted by organisations worldwide, GRADE provides a system for rating 
quality of evidence and strength of recommendations that is structured and ex-
plicit [8].
The process of formulating the recommendations includes the following steps:
1) Prioritisation of the European Breast Guidelines questions–The JRC compiles 
an extensive list of potential questions, which is completed by the GDG and after 
a public consultation and relevant modifications, the list is submitted for rating 
8. http://ecibc.jrc.ec.europa.eu/gdg-documents.
9. http://www.gradeworkinggroup.org.
3. Methods
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by the GDG members. The GDG agrees on the final list of prioritised questions 
at a physical meeting.
2) Framing the questions–The GDG formulates the questions according to a 
standard structured format, generally called PICO format, which stands for: Pop-
ulation under study; Intervention; Comparator: other main options; and Out-
comes that are important to consumers and relevant stakeholders. The GDG de-
fines the components of each question. In the case of the outcomes, the JRC 
prepares a dedicated prioritisation exercise that is then completed online by the 
GDG, and only those outcomes rated as ‘critical’ or ‘important’ for decision mak-
ing are included in the question.
3) Quality of the evidence related to each question–The JRC has outsourced a 
systematic review team according to the usual tendering procedures of the Com-
mission [9]. It is a multidisciplinary group of methodologists, information spe-
cialists, health economists, and qualitative researchers based at the Iberoamerican 
Cochrane Centre–CCIb (GRADE centre, Barcelona, Spain). Each guideline rec-
ommendation is based on the best available body of evidence obtained through 
systematic reviews, which are based on exhaustive search strategies allowing the 
identification of relevant evidence related to each critical or important outcome 
[10] [11] [12] [13]. For each question, the contractor CCIb (systematic review team) 
seeks evidence related to the patient-important outcomes prioritised by the GDG 
as well as the value patients place on those outcomes. In order to do so, already 
existing high quality systematic reviews can be used or de novo systematic reviews 
are conducted, depending on availability of updated and targeted systematic re-
views. CCIb follows a two-step process for rating the quality of evidence: 1) rates 
the overall quality of evidence for each outcome across studies; 2) rates the overall 
quality of evidence for each recommendation across all outcomes. Finally, the sys-
tematic review team produces ‘evidence tables’ summarising the body of evidence 
for each recommendation. The JRC interacts with the GDG and CCIb in order 
to ensure the experts’ inputs are taken into consideration in the evidence findings.
4) Going from the evidence to the recommendation–CCIb, in coordination 
with the JRC, provides evidence-to-decision frameworks (EtDs) to help the GDG 
making recommendations. EtDs include criteria and judgements informed by re-
3. Methods | 15
search evidence and additional considerations. The EtD frameworks are used to 
vote or achieve consensus within the GDG meetings on the criteria that influence 
a recommendation or decision. Then CCIb proposes a neutral draft recommen-
dation. Based on this draft (and on the final EtD framework) the GDG agrees 
on the direction of each recommendation (for or against the particular interven-
tion under study) and its strength (strong or weak-conditional). GRADE defines 
the strength of a recommendation as ‘the extent to which one can be confident 
that the desirable effects of an intervention outweigh its undesirable effects’ [14]. 
Weak-conditional recommendations can be accompanied by a recommendation 
for research in case it should be clear that stronger evidence can be achieved via 
additional/more solid research results.
5) Approval and publication of the European Breast Guidelines recommenda-
tions–All the recommendations and underpinning work, once approved, will be 
made publicly available on the ECIBC web hub. The approval process foresees 
as first step the approval of the recommendation and its framework by the GDG. 
The language of each recommendation is then revised to ensure that the recom-
mendations are clear and understandable to all users, and a specific patient-adapted 
version of the recommendation is also prepared. The JRC has also the responsi-
bility to approve the CCIb deliverables (in short, systematic reviews, participation 
to meetings and formulation of the draft recommendation) both as owner of the 
contract and in view of publication of the recommendations on the ECIBC web 
hub (and, when appropriate, on peer reviewed journals). 
6) Impact on Policies–Vis-à-vis DG SANTE, JRC holds also the responsibility 
to provide evidence that can potentially modify Health Policies in the area of 
breast cancer care, for instance as regards the age-range to be targeted by a popula-
tion-based intervention like breast cancer screening. For this reason, DG SANTE 
is promptly informed in case a policy change may be triggered by the recommen-
dations, and the Expert Group on Cancer Control, supporting the Commission 
for cancer-related policies, is involved as well.
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The GDG has defined the following six chapters within the European Breast Guide­
lines:
Screening 
Diagnosis
Communication
Training
Interventions to reduce inequalities
Monitoring and evaluation of screening and diagnosis.
Each chapter will include specific recommendations, based on the questions, rel-
evant to the target audience, that are prioritised by the GDG. Each chapter is 
produced by dedicated subgroups, all coordinated by the JRC.
JRC drafted the scope of the European Breast Guidelines and after discussion it was 
approved by the GDG. Next, a call for feedback was carried out asking stakehold-
ers for their approval and suggestions for improvements of this first draft scope. 
Taking into account all the comments received, a final version of the scope was 
issued and, once again, approved by the GDG.10
In parallel, and according to the process described in the Methods section, the JRC 
prepared a list of possible PICOs to be prioritised that included questions gener-
ated by the GDG as well as those suggested by stakeholders, and fitting with the 
GDG scope, during the above mentioned call for feedback. This prioritised list 
includes a maximum of 90 questions for the complete European Breast Guidelines.
During the next step, under JRC coordination, the prioritised PICOs are again 
discussed within the subgroups, working on the corresponding chapters of the 
European Breast Guidelines, as many questions were given similar ratings during 
10. Available online at: http://ecibc.jrc.ec.europa.eu/european-guidelines.
4. Results
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the first GDG prioritisation exercise, were not clearly understood by the entire 
GDG or are, in reality, equivalent to more than one PICO question (because the 
question included more than one intervention or more than one population). 
Therefore, a second prioritisation step was needed. After the adequately framed 
questions are agreed on, the outcomes for each of those questions are able to be 
prioritised and CCIb is able to search for the evidence for each of the questions. 
This evidence is presented to the GDG for discussion and agreement on the evi-
dence-to-decision frameworks (EtDs).
Other related activities and processes complementing the workflow include calls 
for feedback (on the scope of the European Breast Guidelines, on the final recom-
mendations), management of conflict of interests, organisation of meetings and 
on-line voting, collaboration with other ongoing projects.
As a result of this complex process, which involves a wide range of experts, pa-
tients and policy makers, final recommendations are formulated.
The recommendations will be issued in significant groups of questions–the first 
set to be published are on the relevant screening ages, which will be followed by 
recommendations on other interventions in screening diagnosis, communication, 
etc.
The recommendations will be also adapted to be informative not only for clini-
cians, but for patients/citizens and for policy makers, as well. All of these recom-
mendations will be made publicly available on a dedicated web page, and in the 
future will be translated into all European languages.
4.1. Overview of transparency and independence in the European Breast 
Guidelines (and ECIBC) context
Identifying and managing conflict of interest (CoI) of contributors is a key attrib-
ute and requirement for trustworthy guidelines and reduces the risk of bias in the 
development of recommendations [8]. Preventive actions were taken to ensure 
independence of the GDG: (i) GDG members and contributors are nominated 
through a transparent and open process; (ii) GDG members and contributors act 
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upon their personal capacity and do not represent any entity or affiliation; (iii) 
GDG members and contributors, have to sign a confidentiality and a commit-
ment form, implying that the content of the meetings’ discussions and decisions 
taken in the context of the ECIBC cannot be disclosed during the mandate and 
in the future–this helps protecting them from possible pressures from external 
groups of interest.
The outsourcing of systematic reviews can as well be considered as part of the 
preventive actions contributing to improve the independence of the work done 
by the GDG under the coordination of the JRC.
As corrective measures, CoI of all GDG members and other contributors are as-
sessed and managed by the JRC following an established procedure in line with 
the EC rules [15] and their participation in the development/approval of the re-
spective recommendations is limited accordingly.
4.2. Procedure to maintain the evidence-based recommendations for breast 
cancer services up-to-date in the long term
The JRC will define a methodology to assess the need and frequency for updating 
the European Breast Guidelines in order to ensure that they are based on the best 
available and up-to-date evidence. Fig. 3 shows the lifecycle of this process.
4.3. Impact of the recommendations on the EU policy regarding cancer
The fight against cancer, in this case breast cancer, requires cooperation at EU-level, 
which has proven to be of added value in the past.
The comprehensive approach, promoted by EU [16], to tackling the chronic dis-
ease burden, including breast cancer, in Europe will benefit from the development 
of evidence-based recommendations in several different ways, corresponding to 
the main areas covered by the European Breast Guidelines, summarised in Table 1.
In the Commission Communication on Action Against Cancer: European Part-
nership [4], a goal was set to reduce the burden of cancer by achieving 100% 
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Fig. 3. Guidelines lifecycle.
population coverage of screening for breast, cervical and colorectal cancer. In 
addition, the European Parliament Declaration on the fight against breast cancer 
in the European Union [6], emphasised the importance of reducing the breast 
cancer mortality rate.
Therefore, the major impact of the European Breast Guidelines on EU policy is fore-
seen to be seen in the screening area. Screening is a population-based intervention 
and, for instance, screening recommendations concerning the different age-ranges 
of women to be invited/covered by screening an
or the different techniques to be used may have a great impact on health policies 
across Europe.
However, the recommendations related to diagnosis, where costly investments 
may or may not be required, will also be of interest for policy makers.
The development of European Breast Guidelines will also contribute to several EU 
initiatives [14] targeting the following issues:
Research gaps Development
Updating
Monitoring
Implementation dissemination
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Table 1. Potential impact of the European Breast Guidelines on EU cancer policy and initiatives.
11. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2009:0567:FIN:EN:HTML.
12. http://ec.europa.eu/health/major_chronic_diseases/indicators/index_en.htm.
13. http://ec.europa.eu/health/major_chronic_diseases/diseases/cancer/index_en.htm#fragment2.
14. http://ec.europa.eu/health/major_chronic_diseases/diseases/cancer/index_en.htm#fragment3.
EU initiatives to tackle 
breast cancer burden 
in Europe [13]
Areas, covered by the European Breast Guidelines
Activity Topic/Chapter
Reduce the burden 
of cancer by achieving 
100% population 
coverage of screening 
for breast cancer [4]
The Communication chapter of the European Breast 
Guidelines will include evidence-based recommen-
dations about the appropriate approach for inform-
ing society, individuals and high-risk groups about 
the benefits and harms of screening. In addition, 
the Monitoring and evaluation chapter will include 
indicators for measuring the effectiveness of the 
screening programme. The recommendations re-
garding reducing inequalities will also contribute to 
increasing the population coverage of screening.
Communication;
Monitoring and eval-
uation of screening 
and diagnosis;
Interventions to 
reduce inequalities
Systematically integrat-
ing policy and action 
to reduce inequalities 
in health 11
A dedicated chapter of the European Breast Guide-
lines will include evidence-based recommendations 
to reduce inequalities in screening and diagnosis
Interventions 
to reduce inequalities
Making national sta-
tistics 12 as reliable and 
com parable as possible, 
so they can serve as 
a good guide to policy 
effectiveness
The experts, contributing to Monitoring and evalua-
tion chapter of the European Breast Guidelines will 
define process and outcome indicators, which will be 
comparable between countries and will be potential-
ly monitored at population level in order to meas-
ure the effectiveness of the relevant interventions 
regarding screening and diagnosis
Monitoring 
and evaluation 
of screening 
and diagnosis
Supporting public-
aware ness-raising 
and disease-prevention 
campaigns that actively 
target high-risk groups 
and individuals
The Communication chapter of the European Breast 
Guidelines will include evidence-based recommen-
dations about the appropriate approach for inform-
ing society, individuals and high-risk groups about 
benefits and harms of screening
Communication
Expert Group on Cancer 
Control 13
Updated regularly on the status of the process of 
development of the European Breast Guidelines and 
are expected to facilitate the implementation of 
recommendations at national level.
All chapters
European Code Against 
Cance114
The development and the constant update of the 
European Breast Guidelines may facilitate the imple-
mentation of the screening recommendations
Screening
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• Inequalities in health15 –a dedicated chapter of the European Breast Guidelines 
will include evidence-based recommendations to reduce inequalities in screen-
ing and diagnosis.
• Making national statistics16 as reliable and comparable as possible, so they 
can serve as a good guide to policy effectiveness–the experts, contributing to 
Monitoring and evaluation chapter of the European Breast Guidelines will define 
process and outcome indicators, which will be comparable between countries 
and will be potentially monitored at population level in order to measure the 
effectiveness of the relevant interventions regarding screening and diagnosis.
• Supporting public-awareness-raising campaigns that actively target high-risk 
groups and individuals–the Communication chapter of the European Breast 
Guidelines will include evidence-based recommendations about the appropriate 
approach for informing society, individuals and high-risk groups about benefits 
and harms of screening.
The recommendations, included in the European Breast Guidelines, will comple-
ment also other outputs, resulting from EU-level cooperation, such as:
• the European Guide on Quality Improvement in Comprehensive Cancer Control, de-
veloped by the CANCON Joint Action 2014-2017 [17].17
• the EPAAC–European Partnership for Action Against Cancer (2009-2013) [18],18 
aiming to help Member States and other stakeholders to tackle cancer more 
efficiently.
In 2014, the Commission established the Expert Group on Cancer Control [19],19 
which includes representatives of the Member states. They have been updated reg-
ularly on the status of the development of the European Breast Guidelines and are 
expected to facilitate the implementation of recommendations at national level.
15. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2009:0567:FIN:EN:HTML.
16. http://ec.europa.eu/health/major_chronic_diseases/indicators/index_en.htm.
17. http://cancercontrol.eu/index.php.
18. http://ec.europa.eu/health/major_chronic_diseases/diseases/cancer/index_en.htm#fragment1.
19. http://ec.europa.eu/health/major_chronic_diseases/diseases/cancer/index_en.htm#fragment2.
22 | European Guidelines for Breast Cancer Screening and Diagnosis
As a result from another international collaboration–with IARC, the European 
Code Against Cancer [20]20 was developed, based on the latest scientific evidence. 
Among the set of 12 recommendations on how people can take action to reduce 
their cancer risk is the one about participation in organised breast cancer screen-
ing programmes. Therefore, the development and the constant update of the Eu­
ropean Breast Guidelines may contribute to the successful implementation of this 
recommendation.
To summarise, the European Breast Guidelines, and the ECIBC as a whole, are 
expected to impact on breast cancer care and on policies aiming to reduce the 
burden of the disease. An overall view of the expected impacting modalities is 
provided in Table 1.
20. http://ec.europa.eu/health/major_chronic_diseases/diseases/cancer/index_en.htm#fragment3.
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The GDG, under the JRC coordination, is developing recommendations relevant 
for screening and diagnosis in breast cancer along the six chapters foreseen for the 
European Breast Guidelines.
These recommendations together with all the supporting information (e.g. evi-
dence tables, justification, subgroup considerations, implementation considera-
tions, research priorities, references) will be published in a lay-person language 
on the ECIBC web hub.21 Publications in peer reviewed journals derived e.g. from 
systematic reviews executed for the development of the European Breast Guidelines 
are also planned in agreement with the contributing GDG members, CCIb, and 
DG SANTE.
All this work will serve DG SANTE in their support to the national policies re-
garding breast cancer control and can be used as an example for an appropriate 
approach to be applied also for other types of cancers or other diseases.
21. Available online at: http://ecibc.jrc.ec.europa.eu/european-guidelines.
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CANCON Cancer control joint action
CCIb Iberoamerican Cochrane Centre
DG SANTE European Commission Directorate-General Health and Food Safety
EC European Commission
ECIBC European Commission Initiative on Breast Cancer
EPAAC European Partnership for Action Against Cancer
EtD Evidence-to-decision framework
EU European Union
GDG Guidelines Development Group
GRADE Grading of Recommendations Assessment, Development and 
 Evaluation–a system for rating quality of evidence and strength of 
 recommendations that is structured and explicit
JRC Joint Research Centre
QA Scheme European Quality assurance scheme for breast cancer services
QASDG Quality assurance scheme development group
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Fig. 1.  Contribution of the European Breast Guidelines to EU initiatives.
Fig. 2.  The workflow for production of evidence­based recommendations, included in 
    the European Breast Guidelines.
Fig. 3.  Guidelines lifecycle.
Table 1. Potential impact of the European Breast Guidelines on EU cancer policy and 
    initiatives.
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